Research
Research Experience – Trainees & Research Emphasis - Faculty
At least twelve months are devoted primarily for research activities, and as much time as possible is taken during clinical time to expand upon the research experience.
Each Fellow, under the guidance of a faculty advisor, chooses a research opportunity from the ongoing laboratory and clinical research programs in operation within the division.
Major focus of research include:
- Translational research
- Chronic liver disease
- Parenteral/enteral nutrition
- Chronic viral hepatitis
- Colorectal cancer
Specific Research Techniques:
- Molecular biology
- Immunologic assays
- Biochemical analysis – all laboratory based.
- Endoscopic specialties – ERCP (diagnostic and therapeutic)
- EUS
- Motility
- Video Capsule Endoscopy
Some of the Division's Current Research Grants:
- 2006–2008 - Roche Pharm., Inc. Randomized, multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360ug Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg.
- 2007–2009 - Phase 2 Single Arm Pilot Study to Evaluate the Feasibility of Lycopene Administered in Conjunction with Standard Chronic Hepatitis C Treatment in African-Americans. PI, Not externally funded. Will be conducted within the institution in collaboration with Omer Kucuk, M.D., Oncology.
- 2006-2009 - Salix Pharmaceuticals. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550mg BID for 6 Months in Preventing Hepatic Encephalopathy.
- 2008–2011 - GSK. TPL103922: Phase III, Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with Hepatitis C Virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (pegylated interferon plus ribavirin) ENABLE 1 (Eltrombopag to Initate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver Disease.
- 2008–2011 - GSK. TPL108390 Phase III, Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin) ENABLE 2 (Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C Related Liver Disease.
-
2003–2008 - 1 RO1 CA 101870 – 01; NIH/NCI
Title: Targeting Akt/NF-B Pathways for Pancreatic Cancer Therapy -
2004-2008 - Department of Veterans Affairs (VA Merit Review )
Title: Colorectal Adenoma: Chemoprevention by Folic Acid. -
2005-2009 - Department of Veterans Affairs (VA Merit Review)
Title: EGFR Related Peptide as a Novel Therapy for Colon Cancer - 2007-2012 - 5 RO1 AG14343; National Institutes of Health/National Institute of Aging Title: The Aging Gut: Regulation of Cell Proliferation
Recent Awards:
Milton Mutchnick, M.D.
- Selected as a “Top Doc’ by Hour Magazine, 2006, 2007
- Honoree, AGA Foundation Mentors Research Scholar Award for 2007
- Listed in Best Doctors in America, 2006, 2007 (Best Doctors, Inc)
- Listed in America's Top Doctors, Castle Connolly Medical Ltd, 2006, 2007
- Inducted as a Fellow in the American Gastroenterological Association, Feb. 1, 2008
Adhip Majumdar, Ph.D.
- 2006 Outstanding Merit Certificate, John D. Dingell VA Medical Center, Detroit, MI
- 2007 Research Excellence Award, School of Medicine, Wayne State University, Detroit, MI
- 2007 Outstanding Merit Certificate, John D. Dingell VA Medical Center, Detroit, MI
Firdous Siddiqui, M.D.
- 2005 Dean’s Award for Excellence in Teaching